Anixa Biosciences Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset
Anixa Biosciences (NASDAQ: ANIX) announced its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset. The company aims to diversify holdings while maintaining its ongoing stock buyback program. Management highlighted positive results from their breast cancer vaccine and ovarian cancer therapy clinical trials, emphasizing low cash burn rates. The decision to invest in Bitcoin is presented as part of their financial management strategy, with the company citing Bitcoin's growing recognition as a mainstream asset class, inflation-resistant qualities, and the recent approval of Bitcoin ETFs as supporting factors.
Anixa Biosciences (NASDAQ: ANIX) ha annunciato che il suo Consiglio di Amministrazione ha approvato l'acquisto di Bitcoin come asset di riserva del tesoro. L'azienda mira a diversificare le proprie partecipazioni mantenendo il suo programma di riacquisto di azioni. La direzione ha evidenziato risultati positivi dai loro trial clinici sul vaccino per il cancro al seno e la terapia per il cancro ovarico, sottolineando tassi di consumo di cassa contenuti. La decisione di investire in Bitcoin è presentata come parte della loro strategia di gestione finanziaria, con l'azienda che cita il riconoscimento crescente di Bitcoin come una classe di asset mainstream, le sue qualità di resistenza all'inflazione e il recente approvazione degli ETF su Bitcoin come fattori di supporto.
Anixa Biosciences (NASDAQ: ANIX) anunció que su Junta de Directores ha aprobado la compra de Bitcoin como un activo de reserva de tesorería. La compañía busca diversificar sus participaciones mientras mantiene su programa de recompra de acciones en curso. La dirección destacó resultados positivos de sus ensayos clínicos sobre la vacuna contra el cáncer de mama y la terapia para el cáncer de ovario, enfatizando tasas de quema de efectivo bajas. La decisión de invertir en Bitcoin se presenta como parte de su estrategia de gestión financiera, citando el creciente reconocimiento de Bitcoin como una clase de activo convencional, sus cualidades resistentes a la inflación, y la reciente aprobación de los ETFs de Bitcoin como factores de apoyo.
Anixa Biosciences (NASDAQ: ANIX)는 이사회가 비트코인을 재무 자산으로 구매하는 것을 승인했다고 발표했습니다. 회사는 지속적인 자사주 매입 프로그램을 유지하면서 보유 자산을 다각화하는 것을 목표로 하고 있습니다. 경영진은 유방암 백신 및 난소암 치료 임상 시험의 긍정적인 결과를 강조하며, 현금 소모율이 낮다는 점을 부각시켰습니다. 비트코인에 투자하기로 한 결정은 회사의 재무 관리 전략의 일환으로 제시되며, 비트코인이 주류 자산 클래스로서 인정받고 있는 증가, 인플레이션 저항 특성, 그리고 최근 비트코인 ETF 승인과 같은 지원 요인을 언급하고 있습니다.
Anixa Biosciences (NASDAQ: ANIX) a annoncé que son Conseil d'Administration a approuvé l'achat de Bitcoin en tant qu'actif de réserve de trésorerie. L'entreprise vise à diversifier ses avoirs tout en maintenant son programme de rachat d'actions en cours. La direction a souligné des résultats positifs de leurs essais cliniques concernant le vaccin contre le cancer du sein et le traitement du cancer de l'ovaire, en mettant en avant des taux de consommation de liquidités faibles. La décision d'investir dans Bitcoin est présentée comme partie de leur stratégie de gestion financière, l'entreprise citant la reconnaissance croissante de Bitcoin en tant que classe d'actifs grand public, ses qualités de résistance à l'inflation et la récente approbation des ETF Bitcoin comme des facteurs de soutien.
Anixa Biosciences (NASDAQ: ANIX) hat bekannt gegeben, dass der Vorstand den Kauf von Bitcoin als Reservemittel genehmigt hat. Das Unternehmen plant, seine Bestände zu diversifizieren, während es sein laufendes Aktienrückkaufprogramm aufrechterhält. Das Management hob positive Ergebnisse aus ihren klinischen Studien zur Brustkrebsimpfung und zur Behandlung von Eierstockkrebs hervor und betonte niedrige Barverbrennungsraten. Die Entscheidung, in Bitcoin zu investieren, wird als Teil ihrer finanziellen Managementstrategie präsentiert, wobei das Unternehmen das wachsende Ansehen von Bitcoin als Mainstream-Asset-Klasse sowie dessen inflationsresistente Eigenschaften und die kürzliche Genehmigung von Bitcoin-ETFs als unterstützende Faktoren anführt.
- Strong balance sheet with excess cash reported
- Ongoing stock buyback program in place
- Positive clinical trial results for both breast and ovarian cancer programs
- Low cash burn rate maintained during trials
- Exposure to volatile cryptocurrency market through Bitcoin investment
With Anixa's strong balance sheet and excess cash, this strategic decision aims to diversify the Company's treasury holdings while positioning Anixa to benefit from the potential long-term value of digital assets.
The Company also reaffirmed its ongoing stock buyback program as part of its commitment to enhancing shareholder value.
"We are pleased to add this asset class as an investment option for us. We are thrilled that both of our clinical trials—a breast cancer vaccine (NCT04674306), and an ovarian cancer therapy treating recurrent and resistant patients (NCT05316129)—have produced results that have exceeded our expectations. We are proud of our strategy to move our trials forward, while burning relatively low levels of cash. Our decision about Bitcoin is an additional approach to prudent financial management, enabling greater shareholder value," said Dr. Amit Kumar, CEO of Anixa.
"As we continue to execute on our mission of advancing life-changing cancer therapies, we are also focused on creating long-term financial value for our shareholders," said Mike Catelani, President and CFO of Anixa. "With Bitcoin's growing recognition as a mainstream asset class, we believe it represents a valuable addition to our treasury reserve strategy. The approval of Bitcoin ETFs and increasing participation from institutional investors highlight its rising importance in global markets. Its unique inflation-resistant qualities and potential as a reliable store of value aligns with our goal of optimizing long-term financial stability and growth. Combined with our stock buyback program, this initiative reflects our confidence in the Company's growth trajectory and our dedication to delivering shareholder returns."
For those interested in learning more about the Company, a 30-minute presentation given at a recent investor conference is available on the Company's website at https://ir.anixa.com/events, or at the conference organizer's web page here: Webinar Registration - Zoom.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-board-of-directors-approves-purchase-of-bitcoin-as-treasury-reserve-asset-302313759.html
SOURCE Anixa Biosciences, Inc.
FAQ
Why did Anixa Biosciences (ANIX) decide to invest in Bitcoin?
What clinical trials is Anixa Biosciences (ANIX) currently conducting?
How is Anixa Biosciences (ANIX) managing shareholder value?
